First patient dosed with STORM Therapeutics cancer drug – Business Weekly

Entries now being accepted
Read the latest edition online
The 50 hottest disruptive technology companies
STORM Therapeutics reveals that the first cancer patient has been dosed with STC-15, the Cambridge biotech company’s first-in-class clinical candidate.
An orally bioavailable, highly selective METTL3 inhibitor, STC-15 is the first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development. 
This Phase 1 study is a multiple ascending dose escalation trial aiming to enrol 40-60 patients to measure safety, pharmacokinetics, target engagement, biomarkers related to mechanism and anti-tumour efficacy in patients with solid tumours. 
Preclinical activity was demonstrated with STC-15 through direct cytotoxic and anti-cancer immune response mechanisms in solid tumour and leukaemia models. 
Data indicated enhanced interferon signalling and synergy with T cell checkpoint blockade as an important mechanism of action of STC-15 resulting in tumour regression and anti-cancer immunity in rodent models.
Dr Jerry McMahon, CEO of STORM Therapeutics, said: “This is a major milestone for STORM as we enter clinical development with our lead candidate STC-15 and continue progressing a pipeline targeting RNA modifying enzymes beyond METTL3. 
“We intend to exhibit preclinical data related to STC-15 at future medical conferences this year as we execute our Phase 1 study in patients with solid tumours. We anticipate presenting results from our Phase 1 study in 2023.”
STORM has more than just life science excellence to recommend it. The business also has first rate investment and collaboration backers.
investors include M Ventures (the corporate venture capital arm of Merck KGaA in Germany), Pfizer Ventures, Taiho Ventures LLC, Cambridge Innovation Capital, Seroba Life Sciences, IP Group plc, Fast Track Initiative and the University of Tokyo Innovation Platform.
Michael Anstey, Partner at Cambridge Innovation Capital, says: “Today’s announcement from STORM Therapeutics is a hugely exciting and novel development in the use of biotechnology and RNA modifying enzymes for the treatment of cancer.
“It is another great example of the STORM team translating world-class science from the University of Cambridge into effective treatments in oncology and beyond. 
“We are delighted to continue to support Dr McMahon and his team as it progresses more of Storm’s programmes further towards the clinic.”
Stay informed of the latest news and features


Leave a Comment

Your email address will not be published. Required fields are marked *

Lakers sign Thomas Bryant Tom Brady hint at unretirement this year Kevin Durant trade Warriors stars Brooklyn Nets to sign T.J. Warren ‘Minions’ Fire With $110.5 Million debut